Joint Formulary & PAD

Ruxolitinib - Vitiligo

You are here : Home > Formulary Search > Ruxolitinib - Vitiligo

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Cream
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
ICB
NICE
R
SPC
Restrictions / Comments :
Important

Initiation and prescribing by dermatology specialists only

Documentation

NICE Technology Appraisal
NICE TA1140 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
Evidence Review
Ruxolitinib for vitiligo- Briefing paper- June 2026.doc

PAD Profile

ChemicalSubstance :
Ruxolitinib
Indication :
Vitiligo
Group Name :
Keywords :
skin, dermatology, repigmentation, skin colour,
Brand Names Include :
Opzelura
Important Information :
Latest Additions Date From :
02 Jun 2026
Latest Additions Date To :
31 Jul 2026
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

02 Jun 26 - Surrey & Sussex Area Prescribing Committee (APC)

The Surrey and Sussex Integrated Care Board Aread Prescribing Committee supports restricted use of topical ruxolitinib for the treatment of non-segmental vitiligo with facial involvement in patients aged ≥12 years, in line with NICE TA1140, where standard topical therapies (e.g. potent corticosteroids and/or calcineurin inhibitors) are ineffective, not tolerated, or not appropriate.

Use should be initiated and supervised by a specialist dermatologist with experience in vitiligo management.

Other Indications

Below are listed other indications that Ruxolitinib is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Vitiligo.

  • No records returned.